Cancer treatment-induced bone loss

키워드

참고문헌 (119)

1. D’Oronzo S, "Cancer treatment-induced bone loss(CTIBL) : pathogenesis and clinical implications", Cancer Treat Rev, 41, pp.798~808 (2015)
2. Rachner TD, "Bone health during endocrine therapy for cancer", Lancet Diabetes Endocrinol, 6, pp.901~910 (2018)
3. Hadji P, "Management of Aromatase Inhibitor-Associated Bone Loss(AIBL)in postmenopausal women with hormone sensitive breast cancer : Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG", J Bone Oncol, 7, pp.1~12 (2017)
4. den Uyl D, "Advances in glucocorticoid-induced osteoporosis", Curr Rheumatol Rep, 13, pp.233~240 (2011)
5. Greenfield DM, "Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study", J Clin Endocrinol Metab, 92, pp.3476~3482 (2007)
6. Emens LA, "Cancer immunotherapy : opportunities and challenges in the rapidly evolving clinical landscape", Eur J Cancer, 81, pp.116~129 (2017)
7. Postow MA, "Immune-related adverse events associated with immune checkpoint blockade", N Engl J Med, 378, pp.158~168 (2018)
8. Pantano F, "Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors : an exploratory analysis", J Bone Oncol, 37, pp.100459~ (2022)
9. Johnell O, "An estimate of the worldwide prevalence and disability associated with osteoporotic fractures", Osteoporos Int, 17, pp.1726~1733 (2006)
10. Khan MN, "Cancer treatment-related bone loss : a review and synthesis of the literature", Curr Oncol, 15(Suppl 1), pp.S30~S40 (2008)
11. Raisz LG, "Physiology and pathophysiology of bone remodeling", Clin Chem, 45(8 Pt 2), pp.1353~1358 (1999)
12. You L, "Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading", Bone, 42, pp.172~179 (2008)
13. Roodman GD, "Mechanisms of bone metastasis", N Engl J Med, 350, pp.1655~1664 (2004)
14. Goltzman D, "Physiology of the calcium-parathyroid hormone-vitamin D axis", Front Horm Res, 50, pp.1~13 (2018)
15. Higano CS, "Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer : what do we really know?", Nat Clin Pract Urol, 5, pp.24~34 (2008)
16. Ginaldi L, "Osteoporosis, inflammation and ageing", Immun Ageing, 2, pp.14~ (2005)
17. Buckley L, "Glucocorticoid-induced osteoporosis", N Engl J Med, 379, pp.2547~2556 (2018)
18. Takahashi S, "Management of cancer treatment-induced bone loss(CTIBL)in patients with breast cancer or prostate cancer", J Bone Miner Metab, 41, pp.307~316 (2023)
19. Gradishar WJ, "NCCN Guidelines ® Insights : breast cancer, version 4. 2023", J Natl Compr Canc Netw, 21, pp.594~608 (2023)
20. Spring LM, "Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer : past, present, and future", Lancet, 395, pp.817~827 (2020)
21. Harbeck N, "Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer : updated efficacy and Ki-67 analysis from the monarchE study", Ann Oncol, 32, pp.1571~1581 (2021)
22. Powles TJ, "Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women", J Clin Oncol, 14, pp.78~84 (1996)
23. Stumpf U, "Incidence of fractures in young women with breast cancer-a retrospective cohort study", J Bone Oncol, 18, pp.100254~ (2019)
24. Dowsett M, "Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen", J Clin Oncol, 28, pp.509~518 (2010)
25. Pagani O, "Adjuvant exemestane with ovarian suppression in premenopausal breast cancer", N Engl J Med, 371, pp.107~118 (2014)
26. Hadji P, "Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis", Crit Rev Oncol Hematol, 69, pp.73~82 (2009)
27. Eastell R, "Effect of anastrozole on bone mineral density : 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230", J Clin Oncol, 26, pp.1051~1057 (2008)
28. BIG 1-98 Collaborative Group, "Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer", N Engl J Med, 361, pp.766~776 (2009)
29. Coleman RE, "Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study(IES) : a randomised controlled study", Lancet Oncol, 8, pp.119~127 (2007)
30. Amir E, "Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients : a systematic review and meta-analysis", J Natl Cancer Inst, 103, pp.1299~1309 (2011)
31. Lee YK, "Osteoporotic fractures of the spine, hip, and other locations after adjuvant endocrine therapy with aromatase inhibitors in breast cancer patients : a meta-analysis", J Korean Med Sci, 35, pp.e403~ (2020)
32. Cuzick J, "Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer : 10-year analysis of the ATAC trial", Lancet Oncol, 11, pp.1135~1141 (2010)
33. Goldvaser H, "Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer : a systematic review and meta-analysis", J Natl Cancer Inst, 110, pp.31~39 (2018)
34. Sverrisdóttir A, "Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy", J Clin Oncol, 22, pp.3694~3699 (2004)
35. Kalder M, "Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss : results of the ProBONE II substudy", Osteoporos Int, 26, pp.353~360 (2015)
36. Gnant M, "Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer : 5-year follow-up of the ABCSG-12 bone-mineral density substudy", Lancet Oncol, 9, pp.840~849 (2008)
37. Yoneda K, "Influence of adjuvant anastrozole on bone mineral density in Japanese postmenopausal breast cancer patients : is there a racial difference?", Ann Oncol, 17, pp.1175~1176 (2006)
38. Iuliani M, "Biological effects of cyclin-dependent kinase inhibitors ribociclib, palbociclib and abemaciclib on breast cancer bone microenvironment", Int J Mol Sci, 23, pp.2477~ (2022)
39. Mitsiades N, "Androgen receptor signaling inhibitors : post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer", Endocr Relat Cancer, 28, pp.T19~T38 (2021)
40. Mohamad NV, "A concise review of testosterone and bone health", Clin Interv Aging, 11, pp.1317~1324 (2016)
41. Kiratli BJ, "Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer", Urology, 57, pp.127~132 (2001)
42. Shahinian VB, "Risk of fracture after androgen deprivation for prostate cancer", N Engl J Med, 352, pp.154~164 (2005)
43. Wallander M, "Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort(FRAILCO)", Osteoporos Int, 30, pp.115~125 (2019)
44. Smith MR, "Gonadotropin-releasing hormone agonists and fracture risk : a claims-based cohort study of men with nonmetastatic prostate cancer", J Clin Oncol, 23, pp.7897~7903 (2005)
45. Morgans AK, "Bone complications among prostate cancer survivors : long-term follow-up from the prostate cancer outcomes study", Prostate Cancer Prostatic Dis, 17, pp.338~342 (2014)
46. Iuliani M, "Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment", Oncotarget, 6, pp.12520~12528 (2015)
47. Nakajima S, "Does the addition of abiraterone to castration affect the reduction in bone mineral density?", In Vivo, 34, pp.3291~3299 (2020)
48. Wu J, "Enzalutamide reduces the bone mass in the axial but not the appendicular skeleton in male mice", Endocrinology, 157, pp.969~977 (2016)
49. Smith MR, "Apalutamide treatment and metastasis-free survival in prostate cancer", N Engl J Med, 378, pp.1408~1418 (2018)
50. Fizazi K, "Darolutamide in nonmetastatic, castration-resistant prostate cancer", N Engl J Med, 380, pp.1235~1246 (2019)
51. Hussain M, "Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer", N Engl J Med, 378, pp.2465~2474 (2018)
52. Swaminathan R, "Magnesium metabolism and its disorders", Clin Biochem Rev, 24, pp.47~66 (2003)
53. Stavraka C, "A study to evaluate the cause of bone demineralization in gynecological cancer survivors", Oncologist, 18, pp.423~429 (2013)
54. Hu XC, "Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer(CBCSG006) : a randomised, open-label, multicentre, phase 3 trial", Lancet Oncol, 16, pp.436~446 (2015)
55. Stava CJ, "Skeletal sequelae of cancer and cancer treatment", J Cancer Surviv, 3, pp.75~88 (2009)
56. Pfeilschifter J, "Osteoporosis due to cancer treatment : pathogenesis and management", J Clin Oncol, 18, pp.1570~1593 (2000)
57. Rana T, "Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFβ", PLoS One, 8, pp.e78043~ (2013)
58. Soleimani R, "Mechanisms of chemotherapy-induced human ovarian aging : double strand DNA breaks and microvascular compromise", Aging(Albany NY), 3, pp.782~793 (2011)
59. Georgiou KR, "Methotrexate chemotherapy reduces osteogenesis but increases adipogenic potential in the bone marrow", J Cell Physiol, 227, pp.909~918 (2012)
60. Georgiou KR, "Attenuated Wnt", β-catenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats, 2012, pp.50, 1223~1233
61. Shandala T, "The role of osteocyte apoptosis in cancer chemotherapy-induced bone loss", J Cell Physiol, 227, pp.2889~2897 (2012)
62. King TJ, "Methotrexate chemotherapy promotes osteoclast formation in the long bone of rats via increased pro-inflammatory cytokines and enhanced NF-κB activation", Am J Pathol, 181, pp.121~129 (2012)
63. Meier L, "Fractures of the proximal tibia associated with longterm use of methotrexate : 3 case reports and a review of literature", J Rheumatol, 37, pp.2434~2438 (2010)
64. Aksnes LH, "Some musculo-skeletal sequelae in cancer survivors", Acta Oncol, 46, pp.490~496 (2007)
65. Mori G, "Bone-immune cell crosstalk : bone diseases", J Immunol Res, 2015, pp.108451~ (2015)
66. Dietrich J, "Corticosteroids in brain cancer patients : benefits and pitfalls", Expert Rev Clin Pharmacol, 4, pp.233~242 (2011)
67. Paccou J, "Alterations in bone mineral density and bone turnover markers in newly diagnosed adults with lymphoma receiving chemotherapy : a 1-year prospective pilot study", Ann Oncol, 25, pp.481~486 (2014)
68. Aggarwal S, "Targeted cancer therapies", Nat Rev Drug Discov, 9, pp.427~428 (2010)
69. Sawyers C, "Targeted cancer therapy", Nature, 432, pp.294~297 (2004)
70. Arora A, "Role of tyrosine kinase inhibitors in cancer therapy", J Pharmacol Exp Ther, 315, pp.971~979 (2005)
71. Druker BJ, "David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies", J Clin Oncol, 21(23Suppl), pp.239s~245s (2003)
72. Capdeville R, "Glivec(STI571, imatinib), a rationally developed, targeted anticancer drug", Nat Rev Drug Discov, 1, pp.493~502 (2002)
73. Reichardt P, "Adjuvant therapy in primary GIST : state-of-the-art", Ann Oncol, 23, pp.2776~2781 (2012)
74. Patel S, "Long-term efficacy of imatinib for treatment of metastatic GIST", Cancer Chemother Pharmacol, 72, pp.277~286 (2013)
75. Vandyke K, "Dysregulation of bone remodeling by imatinib mesylate", Blood, 115, pp.766~774 (2010)
76. Fitter S, "Long-term imatinib therapy promotes bone formation in CML patients", Blood, 111, pp.2538~2547 (2008)
77. O’Sullivan S, "Imatinib mesylate does not increase bone volume in vivo", Calcif Tissue Int, 88, pp.16~22 (2011)
78. Berman E, "Altered bone and mineral metabolism in patients receiving imatinib mesylate", N Engl J Med, 354, pp.2006~2013 (2006)
79. Berman E, "Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors", Leuk Res, 37, pp.790~794 (2013)
80. Alemán JO, "Effects of tyrosine kinase inhibition on bone metabolism : untargeted consequences of targeted therapies", Endocr Relat Cancer, 21, pp.R247~R259 (2014)
81. Gnant M, "Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2", J Natl Cancer Inst, 105, pp.654~663 (2013)
82. Kneissel M, "Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts", Bone, 35, pp.1144~1156 (2004)
83. Moseley KF, "Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton : a seminal case series", J Immunother Cancer, 6, pp.104~ (2018)
84. Filippini DM, "Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors : case series and large-scale pharmacovigilance analysis", Int J Cancer, 149, pp.675~683 (2021)
85. Chandra A, "PTH1-34 alleviates radiotherapy-induced local bone loss by improving osteoblast and osteocyte survival", Bone, 67, pp.33~40 (2014)
86. Baxter NN, "Risk of pelvic fractures in older women following pelvic irradiation", JAMA, 294, pp.2587~2593 (2005)
87. Dybvik E, "Pelvic irradiation does not increase the risk of hip replacement in patients with gynecological cancer. A cohort study based on 8, 507patients", Acta Orthop, 85, pp.652~656 (2014)
88. Wilson SD, "Primary hyperparathyroidism with a history of head and neck irradiation : the consequences of associated thyroid tumors", Surgery, 150, pp.869~877 (2011)
89. Wasilewski-Masker K, "Bone mineral density deficits in survivors of childhood cancer : long-term follow-up guidelines and review of the literature", Pediatrics, 121, pp.e705~e713 (2008)
90. Camacho PM, "American Association of Clinical Endocrinologists", American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update, 2020, pp.26(Suppl 1), 1~46
91. Kanis JA, "Worldwide uptake of FRAX", Arch Osteoporos, 9, pp.166~ (2014)
92. Leslie WD, "Performance of FRAX in women with breast cancer initiating aromatase inhibitor therapy : a registry-based cohort study", J Bone Miner Res, 34, pp.1428~1435 (2019)
93. Datta M, "Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer : a critical review", Oncologist, 17, pp.1171~1179 (2012)
94. van Schoor NM, "Vitamin D deficiency as a risk factor for osteoporotic fractures", Bone, 42, pp.260~266 (2008)
95. Dalla Via J, "The effect of exercise on bone mineral density in adult cancer survivors : a systematic review and meta-analysis", Osteoporos Int, 29, pp.287~303 (2018)
96. Lomax AJ, "Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women : the BATMAN Trial", J Bone Oncol, 2, pp.145~153 (2013)
97. Van Poznak C, "Prevention of aromatase inhibitor-induced bone loss using risedronate : the SABRE trial", J Clin Oncol, 28, pp.967~975 (2010)
98. Brufsky AM, "Final 5-year results of Z-FAST trial : adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole", Cancer, 118, pp.1192~1201 (2012)
99. Coleman R, "Zoledronic acid(zoledronate)for postmenopausal women with early breast cancer receiving adjuvant letrozole(ZO-FAST study) : final 60-month results", Ann Oncol, 24, pp.398~405 (2013)
100. Llombart A, "Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer : 12-month analysis of the E-ZO-FAST trial", Clin Breast Cancer, 12, pp.40~48 (2012)
101. Gnant M, "Endocrine therapy plus zoledronic acid in premenopausal breast cancer", N Engl J Med, 360, pp.679~691 (2009)
102. Hong N, "Protective effect of bisphosphonate on the cortical bone at key locations of the femur in aromatase inhibitor-associated bone loss : A three-dimensional cortical bone mapping study", J Bone Oncol, 32, pp.100409~ (2021)
103. Lester JE, "Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer", Clin Cancer Res, 14, pp.6336~6342 (2008)
104. Brufsky AM, "Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole : Z-FAST study 36-month follow-up results", Clin Breast Cancer, 9, pp.77~85 (2009)
105. Wilson C, "Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE(BIG 01", 04)study, 2018, pp.94, 70~78
106. Valachis A, "Adjuvant therapy with zoledronic acid in patients with breast cancer : a systematic review and meta-analysis", Oncologist, 18, pp.353~361 (2013)
107. Israeli RS, "The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy", Clin Genitourin Cancer, 5, pp.271~277 (2007)
108. Greenspan SL, "Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer : a randomized trial", Ann Intern Med, 146, pp.416~424 (2007)
109. Jones C, "Clinical fracture incidence in metastatic hormone-sensitive prostate cancer(mHSPC)and risk-reduction following addition of zoledronic acid to androgen deprivation therapy(ADT)with or without docetaxel(DOC) : long-term results from 2 phase 3 trials from the STAMPEDE platform protocol", J Urol, 209(Suppl 4), pp.e129~ (2023)
110. Ellis GK, "Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer", J Clin Oncol, 26, pp.4875~4882 (2008)
111. Gnant M, "Adjuvant denosumab in breast cancer(ABCSG-18) : a multicentre, randomised, double-blind, placebo-controlled trial", Lancet, 386, pp.433~443 (2015)
112. Smith MR, "Denosumab in men receiving androgen-deprivation therapy for prostate cancer", N Engl J Med, 361, pp.745~755 (2009)
113. Lovato C, "Emerging anabolic agents in the treatment of osteoporosis", Expert Opin Emerg Drugs, 22, pp.247~257 (2017)
114. Reid DM, "Guidance for the management of breast cancer treatment-induced bone loss : a consensus position statement from a UK Expert Group", Cancer Treat Rev, 34(Suppl 1), pp.S3~S18 (2008)
115. Gralow JR, "NCCN task force report : bone health in cancer care", J Natl Compr Canc Netw, 11(Suppl 3), pp.S1~S50 (2013)
116. Waqas K, "Updated guidance on the management of cancer treatment-induced bone loss(CTIBL)in pre-and postmenopausal women with early-stage breast cancer", J Bone Oncol, 28, pp.100355~ (2021)
117. Shapiro CL, "Management of osteoporosis in survivors of adult cancers with nonmetastatic disease : ASCO clinical practice guideline", J Clin Oncol, 37, pp.2916~2946 (2019)
118. Fukumoto S, "Management manual for cancer treatment-induced bone loss(CTIBL) : position statement of the JSBMR", J Bone Miner Metab, 38, pp.141~144 (2020)

관련 논문AI추천